Skip to main content

Rhythm Pharmaceuticals, Inc.

corporate_fare Company Profile

Rhythm Pharmaceuticals, Inc.

RYTM·NASDAQ·Life Sciences·CIK 0001649904

We are a global, commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases. We develop melanocortin-4 receptor (MC4R) agonists, which are precision medicines for hyperphagia and severe obesity caused by rare MC4R pathway diseases. These diseases include acquired or congenital hypothalamic obesity, Bardet-Biedl syndrome (BBS), and Prader-Willi syndrome (PWS). The MC4R pathway in the brain regulates hunger, caloric intake, and energy expenditure, impacting body weight. Our lead product, IMCIVREE (setmelanotide), is an MC4R agonist for which we hold worldwide rights. It is marketed in the United States, European Union (EU), United Kingdom, Canada, and other countries and regions for certain rare MC4R pathway diseases, including BBS. We are also developing two earlier-stage investigational MC4R agonists with global rights: bivamelagon (formerly LB54640), an oral small molecule, and RM-718, designed for weekly subcutaneous administration. These are designed to be highly selective for MC4R and are not expected to cause hyperpigmentation. We anticipate launching IMCIVREE in the United States in 2026 for acquired hypothalamic obesity, a rare disease caused by hypothalamic injury that may impair MC4R pathway signaling. There are approximately 10,000 patients in the United States living with acquired hypothalamic obesity, with an annual incidence of 500 new cases. Similar prevalence and incidence are observed in Europe, and there are between 5,000 and 8,000 patients in Japan.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 40 items for RYTM at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Rhythm Pharma Reports Robust Long-Term Weight Loss with Setmelanotide in Hypothalamic Obesity, New Bivamelagon Data at ENDO 2026
  • Rhythm Pharma's Setmelanotide Shows Positive Phase 2 Data in Prader-Willi Syndrome
  • Rhythm Pharmaceuticals Reports Strong Q1 Revenue Growth and Advances Global Market Expansion for IMCIVREE
  • Rhythm Pharma Reports Strong Q1 Revenue Growth, Successful IMCIVREE Launch, and European/Japanese Expansion
  • Rhythm Pharma Q1 Revenue Jumps 84% to $60.1M on IMCIVREE Success

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$189.76M
Net Income
-$196.54M
Diluted EPS
-$3.11
Op. Cash Flow
-$115.67M
Free Cash Flow
-$116.63M
Gross Profit
$170.26M
Operating Income
-$192.02M
Cash & Equivalents
$54.3M
Total Debt
$108.18M
Debt / Equity
0.78×
Net Margin
-103.6%
Shares Outstanding
67.21M sh
Source: 10-K · filed 2026-02-26 · accession 0001628280-26-012399
$113.5 +1.01% today
52-week range · as of 2026-11-03 $74.5 – $122.2
Market cap
$7.79B
Volume
1.5M (1.0× avg)
3-mo avg 1.6M
Live data · 2026-11-22 12:45 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RYTM - Filings & News (Page 2)

RYTM
Jun 15, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $89.70
Real-time Price: $113.50 info
Change: +$23.80 (+27%) info
Market Cap: $7.79B info
RYTM
Jun 13, 2026, 8:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $89.02
Real-time Price: $113.50 info
Change: +$24.48 (+27%) info
Market Cap: $7.79B info
RYTM
May 05, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $92.31
Real-time Price: $113.50 info
Change: +$21.19 (+23%) info
Market Cap: $7.79B info
RYTM
May 05, 2026, 7:48 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $92.50
Real-time Price: $113.50 info
Change: +$21.00 (+23%) info
Market Cap: $7.79B info
RYTM
May 05, 2026, 7:36 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $92.00
Real-time Price: $113.50 info
Change: +$21.50 (+23%) info
Market Cap: $7.79B info
RYTM
May 01, 2026, 6:55 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $81.37
Real-time Price: $113.50 info
Change: +$32.13 (+39%) info
Market Cap: $7.79B info
RYTM
Apr 03, 2026, 3:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $86.29
Real-time Price: $113.50 info
Change: +$27.21 (+32%) info
Market Cap: $7.79B info
RYTM
Mar 26, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $81.90
Real-time Price: $113.50 info
Change: +$31.60 (+39%) info
Market Cap: $7.79B info
RYTM
Mar 26, 2026, 9:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $83.78
Real-time Price: $113.50 info
Change: +$29.72 (+35%) info
Market Cap: $7.79B info
RYTM
Mar 20, 2026, 9:20 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $97.65
Real-time Price: $113.50 info
Change: +$15.85 (+16%) info
Market Cap: $7.79B info
RYTM
Mar 19, 2026, 6:30 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $90.31
Real-time Price: $113.50 info
Change: +$23.19 (+26%) info
Market Cap: $7.79B info
RYTM
Mar 16, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $86.00
Real-time Price: $113.50 info
Change: +$27.50 (+32%) info
Market Cap: $7.79B info
RYTM
Mar 02, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $92.66
Real-time Price: $113.50 info
Change: +$20.84 (+22%) info
Market Cap: $7.79B info
RYTM
Mar 01, 2026, 12:31 PM EST
Source: Reuters
Importance Score:
9
Price at Filing: $92.66
Real-time Price: $113.50 info
Change: +$20.84 (+22%) info
Market Cap: $7.79B info
RYTM
Mar 01, 2026, 12:30 PM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $92.66
Real-time Price: $113.50 info
Change: +$20.84 (+22%) info
Market Cap: $7.79B info
RYTM
Feb 26, 2026, 6:11 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $98.07
Real-time Price: $113.50 info
Change: +$15.43 (+16%) info
Market Cap: $7.79B info
RYTM
Feb 26, 2026, 5:37 PM EST
Filing Type: S-3ASR
Importance Score:
8
Price at Filing: $98.07
Real-time Price: $113.50 info
Change: +$15.43 (+16%) info
Market Cap: $7.79B info
RYTM
Feb 26, 2026, 5:02 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $98.07
Real-time Price: $113.50 info
Change: +$15.43 (+16%) info
Market Cap: $7.79B info
RYTM
Feb 26, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $103.00
Real-time Price: $113.50 info
Change: +$10.50 (+10%) info
Market Cap: $7.79B info
RYTM
Jan 09, 2026, 9:06 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $99.84
Real-time Price: $113.50 info
Change: +$13.66 (+14%) info
Market Cap: $7.79B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets